/ALBO

ALBO Stock - Albireo Pharma, Inc.

Q: What is the analyst price target for ALBO?

Analyst price target information is not currently available for ALBO.

Q: What is ALBO's market cap?

Market capitalization information is not currently available for ALBO.

Healthcare|Biotechnology|NASDAQ

$44.15+0.00%

+$0.00 (+0.00%) • Mar 2

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-0.3%upside

Target: $44.02

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALBO

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2021

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.04

52W High$45.23

52W Low$16.02

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2021	FY2020	FY2019	FY2018	FY2017
Revenue	$40.58M	$8.31M	$9.64M	$12.74M	$1,000
Gross Profit	$39.22M	$8.31M	$7.43M	$12.74M	$1,000
Gross Margin	96.7%	100.0%	77.1%	100.0%	100.0%
Operating Income	$-123,485,000	$-96,271,000	$-61,112,000	$-37,890,000	$-24,577,000
Net Income	$-151,349,000	$-118,995,000	$-71,704,000	$-46,111,000	$-24,414,000
Net Margin	-373.0%	-1432.3%	-744.1%	-361.9%	-2441400.0%
EPS	$-7.87	$-7.45	$-5.77	$-3.94	$-3.12

Company Overview

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$49

Average Target

↑ 9.9% Upside

Now

$42

Low

$49

Average

$55

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
January 9th 2023	Wedbush	Downgrade	Neutral	$42← $53
September 8th 2022	Guggenheim	Initiation	Buy	$55

Earnings History & Surprises

ALBO

Beat Rate

42%

Last 19 quarters

Avg Surprise

+41.5%

EPS vs Estimate

Beats / Misses

8/11

Last 12 quarters

Latest EPS

$-0.57

Q1 2023

EPS Surprise History

Q2 21

-29.4%

$-2.29vs$-1.77

Q3 21

+3.6%

$-1.90vs$-1.97

Q4 21

+863.2%

$2.90vs$-0.38

Q1 22

+57.8%

$-0.57vs$-1.35

Q2 22

-18.4%

$-2.19vs$-1.85

Q3 22

-23.6%

$-2.04vs$-1.65

Q4 22

-81.1%

$-1.92vs$-1.06

Q1 23

+68.3%

$-0.57vs$-1.80

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2023	May 15, 2023	$-1.97	—	—	—
Q1 2023	Mar 7, 2023	$-1.80	$-0.57	+68.3%	✓ BEAT
Q4 2022	Nov 8, 2022	$-1.06	$-1.92	-81.1%	✗ MISS
Q3 2022	Aug 15, 2022	$-1.65	$-2.04	-23.6%	✗ MISS
Q2 2022	May 16, 2022	$-1.85	$-2.19	-18.4%	✗ MISS
Q1 2022	Mar 1, 2022	$-1.35	$-0.57	+57.8%	✓ BEAT
Q4 2021	Nov 4, 2021	$-0.38	$2.90	+863.2%	✓ BEAT
Q3 2021	Aug 5, 2021	$-1.97	$-1.90	+3.6%	✓ BEAT
Q2 2021	May 6, 2021	$-1.77	$-2.29	-29.4%	✗ MISS
Q1 2021	Feb 25, 2021	$-1.94	$-1.30	+33.0%	✓ BEAT
Q4 2020	Nov 5, 2020	$-1.51	$-1.96	-29.8%	✗ MISS
Q3 2020	Aug 6, 2020	$-1.69	$-1.38	+18.3%	✓ BEAT
Q2 2020	May 7, 2020	$-1.36	$-2.23	-64.0%	✗ MISS
Q1 2020	Mar 2, 2020	$-1.59	$-0.57	+64.2%	✓ BEAT
Q4 2019	Nov 6, 2019	$-1.56	$-1.73	-10.9%	✗ MISS
Q3 2019	Aug 8, 2019	$-1.43	$-1.35	+5.6%	✓ BEAT
Q2 2019	May 9, 2019	$-1.32	$-1.39	-5.3%	✗ MISS
Q1 2019	Mar 6, 2019	$-1.16	$-1.34	-15.5%	✗ MISS
Q4 2018	Nov 8, 2018	$-0.98	$-1.17	-19.4%	✗ MISS
Q3 2018	Aug 7, 2018	$-0.95	$-1.22	-28.4%	✗ MISS